Drug intelligence / Profile preview

1-(4-hexylphenyl)prop-2-en-1-one

Development stage: Unknown
Lead developer: University of California, San Francisco
Modality: Small Molecules

Overview

**Description:** 1-(4-Hexylphenyl)prop-2-en-1-one is a synthetic small molecule belonging to the class of benzoyl derivatives. It is primarily known as an experimental compound and has not been approved for clinical use in any country. The compound has been studied as an inhibitor of thyroid hormone receptor beta, acting by binding to and inhibiting this nuclear receptor. Its main research interest lies in its potential modulation of thyroid hormone signaling pathways[2][7]. No approved indications or marketed formulations exist for this molecule.

Other names: 1-(4-Hexylphenyl)prop-2-en-1-one1-(4-Hexyphenyl)-2-propane-1-one2-Propen-1-one, 1-(4-Hexylphenyl)-

Targets

THRB (Thyroid hormone receptor beta)THRA (Thyroid hormone receptor alpha)

Beyond the preview

Go deeper on 1-(4-hexylphenyl)prop-2-en-1-one.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1-(4-hexylphenyl)prop-2-en-1-one.

Explore the full profile